TRACY L. BAHL - Corporate Board Profile

TTEC Holdings, Inc.

Filing Date	Source Excerpt
2014-04-08	Tracy L. Bahl was appointed to the Board in 2013 to provide Healthcare vertical expertise. He is an independent director. He does not serve on any committees. His total annual compensation in 2013 was $131,474. He is male as indicated by Mr. Bahl.
2015-04-10	Mr. Bahl serves as the Chair of the Compensation Committee and is a member of the Nominating and Governance Committee. Mr. Bahl currently serves as an executive vice president, health plans for CVS Caremark. Since 2007, Mr. Bahl has served as a special advisor to General Atlantic, a leading global growth equity firm with U.S. $20 billion in capital, and its portfolio companies, including since February 2013, a member of the Board of Directors of MedExpress, a chain of urgent care service centers throughout the United States; and between 2008 and 2011 as the executive chairman for Emdeon, a provider of health information exchange and revenue cycle management solutions. Between 1998 and 2007, Mr. Bahl held various senior executive positions as part of UnitedHealth Group, including between 2004 and 2007 as the chief executive officer of Uniprise, a U.S. $7 billion division of UnitedHealth Group; between 2002 and 2004 as chief marketing officer for UnitedHealth Group; and between 1998 and 2002 as the president of Uniprise Strategic Solutions. Prior to UnitedHealth Group, Mr. Bahl was an executive with CIGNA Healthcare. Board Committees table shows Mr. Bahl as Chair of Compensation Committee and member of Nominating and Governance Committee and Executive Committee. Director Compensation Overview shows total compensation of $162,132.
2016-04-12	Mr. Bahl serves as the Chair of the Compensation Committee and is a member of the Nominating and Governance Committee. Mr. Bahl currently serves as an executive vice president, health plans for CVS Health. Since 2007, Mr. Bahl has served as a special advisor to General Atlantic, a leading global growth equity firm with U.S. $20 billion in capital, and its portfolio companies. Between 2013 and 2015, Mr. Bahl served as a member of the Board of Directors of MedExpress, a chain of urgent care service centers throughout the United States; and between 2008 and 2011 as the executive chairman for Emdeon, a provider of health information exchange and revenue cycle management solutions. Between 1998 and 2007, Mr. Bahl held various senior executive positions as part of UnitedHealth Group, including between 2004 and 2007 as the chief executive officer of Uniprise, a U.S. $7 billion division of UnitedHealth Group; between 2002 and 2004 as chief marketing officer for UnitedHealth Group; and between 1998 and 2002 as the president of Uniprise Strategic Solutions. Prior to UnitedHealth Group, Mr. Bahl was an executive with CIGNA Healthcare. Mr. Bahl also serves as a Trustee and Vice Chairman of the Board of Trustees for Gustavus Adolphus College, in St. Peter, MN.
2017-04-13	Mr. Bahl serves as the Chair of the Compensation Committee and is a member of the Nominating and Governance Committee. Mr. Bahl currently serves as an executive vice president, health plans for CVS Health. Since 2007, Mr. Bahl has served as a special advisor to General Atlantic, a leading global growth equity firm with U.S. $20 billion in capital, and its portfolio companies. Between 2013 and 2015, Mr. Bahl served as a member of the Board of Directors of MedExpress, a chain of urgent care service centers throughout the United States; and between 2008 and 2011 as the executive chairman for Emdeon, a provider of health information exchange and revenue cycle management solutions. Between 1998 and 2007, Mr. Bahl held various senior executive positions as part of UnitedHealth Group, including between 2004 and 2007 as the chief executive officer of Uniprise, a U.S. $7 billion division of UnitedHealth Group; between 2002 and 2004 as chief marketing officer for UnitedHealth Group; and between 1998 and 2002 as the president of Uniprise Strategic Solutions. Prior to UnitedHealth Group, Mr. Bahl was an executive with CIGNA Healthcare. Mr. Bahl also serves as a Trustee and Vice Chairman of the Board of Trustees for Gustavus Adolphus College, in St. Peter, MN. The following table summarizes the actual compensation earned by independent directors during 2016: Steven J. Anenen $256,195, Tracy L. Bahl $199,983, Gregory A. Conley $211,983, Robert N. Frerichs $207,463, Marc L. Holtzman $180,392, Shrikant Mehta $180,994. The employee directors do not receive additional compensation for their Board service.
2018-04-13	Mr. Bahl serves as the Chair of the Compensation Committee and is a member of the Nominating and Governance and Executive Committees. Mr. Bahl currently serves as executive vice president, health plans for CVS Health and has been with CVS Health since November of 2013. Mr. Bahl's extensive experience in the healthcare industry, his public company and private equity experience provide necessary and desired skills, experience and perspective to our Board. His 2017 total compensation was $199,997.
2019-04-12	Mr. Bahl serves as the Chair of the Compensation Committee and as a member of the Nominating and Governance and Executive Committees. ... The following table summarizes the actual compensation earned by independent directors during 2018: Tracy L. Bahl $199,989.
2020-04-03	Mr. Bahl serves as the Chair of the Compensation Committee and as a member of the Nominating and Governance and Executive Committees. Mr. Bahl was previously the President and CEO of OneOncology, a General Atlantic portfolio company. Mr. Bahl's extensive experience in the healthcare industry, his public company and private equity experience bring relevant and necessary skills, experience, and perspective to our Board. 2019 director compensation total $210,605.
2021-04-13	Mr. Bahl serves as the Chair of the Compensation Committee and as a member of the Nominating and Governance and Executive Committees. Mr. Bahl’s extensive experience in the healthcare industry, his public company and private equity experience bring relevant and necessary skills, experience, and perspective to our Board. Independent directors’ compensation in 2020 was $211,006.
2022-04-11	Mr. Bahl’s extensive experience in the healthcare industry, his public company and private equity experience bring relevant and necessary skills, experience, and perspective to our Board. Committees: Compensation (Chair), Nominating and Governance. Compensation: $231,865 in 2021.
2023-04-11	Mr. Bahl’s extensive experience in the healthcare industry and his public company and private equity experience bring relevant and necessary skills, experience, and perspective to our Board. Since 2020, Mr. Bahl has served as an operating partner for the healthcare group at Welsh, Carson, Anderson & Stowe, a private equity firm specializing in healthcare and technology investments (WCAS); and as a managing partner for Valtruis, and member of the board of directors for Wayspring Health, Oncology Care Partners, and Interwell Health, WCAS’ portfolio companies. Previously, Mr. Bahl served as the president and CEO of OneOncology, a General Atlantic portfolio company that provides administrative, operational, and scientific support to oncology practices throughout the U.S. Between 2013 and 2018, Mr. Bahl served as executive vice president, health plans for CVS Health. From 2007 to 2013, he served as a special advisor to General Atlantic, supporting various of its portfolio companies in leadership roles. Prior to 2007, Mr. Bahl held various senior executive positions as part of UnitedHealth Group, and at CIGNA Healthcare. Total compensation for 2022 was $232,487.
2024-04-10	Mr. Bahl’s extensive experience in the healthcare industry and his public company and private equity experience bring relevant and necessary skills, experience, and perspective to our Board. Since 2020, Mr. Bahl serves as an operating partner for the healthcare group at Welsh, Carson, Anderson & Stowe, a private equity firm specializing in healthcare and technology investments; and as a managing partner for Valtruis, and member of the board of directors for Wayspring Health, Oncology Care Partners, and InterWell Health, Valtruis’ portfolio companies. Independent director compensation was $288,738 in 2023.